Boost needed for innovation in Indian pharma, study finds
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
List view / Grid view
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
The European Medicines Agency has issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
The probable carcinogen N-nitrosodimethylamine was detected in Sandoz’s ranitidine capsules, prompting the voluntary move.
Researchers have developed a chikungunya vaccine that can be stored at warm temperatures and manufactured quickly, which has been validated in animal models.
The Jynneos live, non-replicating vaccination for smallpox and monkeypox has been approved by the FDA for high-risk patients.
FDA announces the voluntary recall for the losartan medications has been extended to include more lots, after impurities were found in the drugs.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
King Pharmaceuticals Limited and Alissa Healthcare Research Limited have admitted to sharing information to keep drug prices up.
An event was held last week, exploring the manufacturing and potential of cannabinoids within the pharmaceutical industry.
The EMA has suggested seven treatments to be granted marketing authorisations and also advocated indication extension for eight drugs.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
The British Pharmacopoeia and United States Pharmacopeia partnership is to be formalised to strengthen the quality of medicines and public health.
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.